Saturday, April 13, 2024
Home News Sun Pharma shares: Jefferies sees healthy upside after recent acquisition

Sun Pharma shares: Jefferies sees healthy upside after recent acquisition


Jefferies stated in a note that analyst Dr. alopecia areata during the call with a Jefferies US analyst regarding the Concerta Pharma acquisition and its recent acquisition by Sun Pharma.

They talked about Deuruxolitinib’s potential ramp-up, profitability, drug use, and IP issues. In terms of profitability, Maury stated that the cost of goods sold (COGS) for Deuruxolitinib could be 6-12% of sales price, that marketing expenses could range from $50 million to $100 million (if the product reaches sales of less than USD 500 million), and that the current open-label study and initial OPEX for the product could require annual costs ranging from $20 million to $40 million (we used USD50 million cost for the NPV calculation for Deuruxolitinib). model has been prepared),” read the note. With a target price of Rs, the brokerage maintains a buy rating on Sun Pharma shares. 1,200 each.

Drug significant Sun Pharma finished the obtaining of US-based Show Drugs recently subsequent to consenting to an arrangement to gain the firm in January in a $576 million arrangement.

The brokerage pointed out that Concerta Pharma’s clinical trials indicated that it would compete with competing products from Eli Lilly and Pfizer, and that Phase III data were not available, explaining why Sun got a good deal on Concerta. It was affirmed from Show Pharma had a market capitalization of under $1 billion not long before the end of exchanging.

“Big Pharma dropped the company’s best-in-class product probably due to IP issues surrounding the product, and some of them, such as Lilly, Pfizer, and BMS, have their own program for Alopecia Areata. Additionally, Concert Pharma required a partnership because it lacked a cash runway beyond 2023. Sun Pharma may have been able to get a good deal for the Concert acquisition thanks to the acquisition’s low competitive intensity and Concert’s decreasing cash reserves. o2help does not share the opinions or recommendations expressed above.


Markets end FY23 in style; Sensex Nifty rally nearly 2% on firm global trends

Market, The final day of the fiscal year 2022-23 saw gains for benchmark indices, with a gain of nearly 2% on Friday, extending gains for...

Day trading guide for today: 6 stocks to buy or sell on Friday — 31st March

Trading, Day trading guide for today: Indian shares gained on Wednesday as global markets' increased risk appetite was aided by easing in the banking industry....

Financial, IT stocks aid Indian shares snap three-month losing streak

Financial, By Bharat Rajeshwaran BENGALURU (Reuters) - Indian shares rose on Friday, supported by a higher weighting of financial stocks and information technology (IT) stocks,...


Please enter your comment!
Please enter your name here


Most Popular

Trading the Inside Bar Pattern on Pocket Option Platform

Inside Bar Pattern Introduction Price movement on a chart is examined in price action trading. You may use candlesticks to predict where prices will move...

“Unlocking the Secrets: 4 Tricks of Successful Traders on Pocket Option Platform”

For a year, I have been trading on the Pocket Option platform. I sometimes succeed and sometimes fail. However, I was confident that if...

Identifying Mistakes That Lead to Losses on Pocket Option

Why do people lose their money when trading binary options New traders frequently take a significant financial risk while trading binary options. As a result,...

Weekly Income Plan on Pocket Option Platform”

Get weekly returns on Pocket Option It turned out that October was a terrific month for me. I am still able to generate money every...

Recent Comments